AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03201471
Drug: Chidamide + R-CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
Trial: NCT03475680
Drug: Oral Gentamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Trial: NCT03475680
Drug: Oral placebo Gentamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Trial: NCT01966601
Drug: TRV027 Dose #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 continuous intravenous infusion Dose #1
Trial: NCT01966601
Drug: TRV027 Dose #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 continuous intravenous infusion Dose #2
Trial: NCT01966601
Drug: TRV027 Dose #3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 continuous intravenous infusion Dose #3
Trial: NCT01966601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo continuous intravenous infusion
Trial: NCT01643083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 week
Trial: NCT04096742
Drug: tretinoin 0.05% lotion (Altreno)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altreno topical lotion
Trial: NCT00887406
Drug: Placebo SD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose via nebuliser
Trial: NCT00887406
Drug: GSK961081 100mcg RD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeat dose via nebuliser
Trial: NCT00887406
Drug: GSK961081 300mcg RD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeat dose vai nebuliser
Trial: NCT00887406
Drug: Placebo RD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeat dose via nebuliser
Trial: NCT02242188
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age.
Trial: NCT01903330
Drug: ERC1671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intradermally
Trial: NCT01903330
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
Trial: NCT01903330
Drug: Oral Control (Sucrose pill)
RxNorm normalized name: Afeditab CR Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01862328
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle
Trial: NCT00467584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
Trial: NCT02006147
Drug: TLC399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Trial: NCT03775265
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03498066
Drug: Continuation of the Betablockers (βB) treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use Betablockers treatment
Trial: NCT00547196
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01572961
Drug: acetylsalicilic acids (Aspirin)
RxNorm normalized name: ascorbic acid / aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 1g.
Trial: NCT01572961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02778178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL saline 0.9%, per side
Trial: NCT01483872
Drug: NAC/Tigecycline/Heparin combination lock solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02398461
Drug: rHIgM22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IV infusion
Trial: NCT02398461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01394458
Drug: Heparin 1000 u / ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
Trial: NCT00215982
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
Trial: NCT04345471
Drug: Desvenlafaxine 100 mg
RxNorm normalized name: desvenlafaxine 100 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily dosing for 8 weeks
Trial: NCT04345471
Drug: Desvenlafaxine 50 mg
RxNorm normalized name: desvenlafaxine 50 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily dosing for 8 weeks
Trial: NCT04345471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily dosing for 8 weeks
Trial: NCT00851045
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Trial: NCT03623256
Drug: Spinal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
Trial: NCT00634179
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m²
Trial: NCT00634179
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m²
Trial: NCT03804645
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Trial: NCT02260492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose) administered via the Solis dry powder inhaler
Trial: NCT00102869
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg levodopa per day over 10 days/ treatment phase
Trial: NCT00838877
Drug: radioligand [11C]AZD2184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of iv admin. 1 time per subject
Trial: NCT04203680
Drug: HTK cardioplegic solution
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
Trial: NCT04203680
Drug: blood cardioplegia
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
Trial: NCT04324359
Drug: SURF-201
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop twice daily (BID) in the study eye for 16 days.
Trial: NCT04324359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop twice daily (BID) in the study eye for 16 days.
Trial: NCT00824460
Drug: 1.25 g PA21 (250 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
Trial: NCT00824460
Drug: 5.0 g PA21 (1,000 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Trial: NCT00824460
Drug: 7.5 g PA21 (1,500 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Trial: NCT00824460
Drug: 10.0 g PA21 (2,000 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Trial: NCT00824460
Drug: 12.5 g PA21 (2,500 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Trial: NCT02078063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
Trial: NCT02818361
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00920933
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02617758
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
Trial: NCT02617758
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
Trial: NCT03899259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00225082
Drug: Nucleoside analogue switch
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stavudine switched to tenofovir
Trial: NCT01977430
Drug: Hydrochlorothiazide and furosemide
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
Trial: NCT00191906
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, every day (QD), by mouth (PO)
Trial: NCT03551730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01411267
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Trial: NCT00662688
Drug: Chemotherapy at the investigator's discretion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01152450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/A (two actuations of placebo) delivered via Respimat® inhaler
Trial: NCT04072562
Drug: AZD7594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.
Trial: NCT01756053
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective neuronal nicotinic receptor agonist.
Trial: NCT01756053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules supplied by study drug supplier.
Trial: NCT03470038
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT03038451
Drug: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02563951
Drug: GNS Spray 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02563951
Drug: GNS Spray 1.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02563951
Drug: GNS Spray 2.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01981486
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID modified-release tablets
Trial: NCT04530786
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia
Trial: NCT01617564
Drug: bipuvacain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
Trial: NCT01055249
Drug: Ibuprofen, Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Trial: NCT01055249
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Trial: NCT00299182
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
Trial: NCT00299182
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
Trial: NCT00299182
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
Trial: NCT00299182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Trial: NCT04138849
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, single dose.
Trial: NCT03639701
Drug: Thymidine
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
Trial: NCT00969254
Drug: Pílulas de Lussen
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo.
Trial: NCT00969254
Drug: Pyridium®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo.
Trial: NCT03229252
Drug: Placebo Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Inhalation Solution
Trial: NCT03229252
Drug: SPX-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPX-101 Inhalation Solution
Trial: NCT01197378
Drug: Cysteamine Bitartrate Delayed-release Capsules
RxNorm normalized name: Cysteamine Bitartrate Delayed-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose.
Trial: NCT02008721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01593527
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg s.c.
Trial: NCT05236946
Drug: Tyrosine kinase inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI
Trial: NCT01466803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Trial: NCT03136991
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
Trial: NCT03136991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
Trial: NCT02058472
Drug: SEVIKAR®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092768
Drug: MK0663, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092768
Drug: Comparator: celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656773
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
Trial: NCT04562610
Drug: Intravenous Infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
Trial: NCT03186729
Drug: Antithrombotic Agent
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant or antiplatelet drugs
Trial: NCT02039479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as ADD-on to every necessary treatment as usual
Trial: NCT00597233
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00597233
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00570856
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/day
Trial: NCT00570856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo similar to the folic acid tablets, 1/day
Trial: NCT00163111
Drug: VFENDÂ® I.V., Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00163111
Drug: Diflucan IV, oral
FDA approved: no
EMA approved: no
PMDA approved: no